CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Trial Parameters
Brief Summary
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.
Eligibility Criteria
Inclusion Criteria: To be eligible to participate in this registry, an individual must meet all the following criteria: 1. Has ever been diagnosed with severe AA by a dermatologist or a qualified dermatology provider. 2. Is 12-17 years of age at the time of enrollment. 3. Is willing to provide consent/assent for participation in the registry. 4. Has been prescribed a new commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe AA in adolescents in the context of routine clinical care that is consistent with local prescribing guidelines and/or regulations for the country where the site is located. A new therapy is a medication that the subject has never taken before. 1. At the time of registry enrollment OR 2. Within 6 months prior to registry enrollment In the opinion of the treating provider, is deemed a candidate for treatment with a commercially available advanced therapy and/or conventional systemic therapy for the treatment of severe